HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Neutral 52.7%

Neg 0% Neu 52.7% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.